Study on Safety of Telbivudine in Treatment of Hepatitis B Virus Transgenic Mice with Pregnancy and Efficacy of Preventing HBV Mother-to-Child

Zhang Qingying,Cheng Haidong,Jiang Peiru,Shen Yan

DOI: https://doi.org/10.3969/j.issn.1008-6358.2010.02.019

2010-01-01

Abstract:Objective:To study the safety of Telbivudine for hepatitis B virus (HBV) transgenic mice with pregnancy and the efficacy of preventing HBV mother-to-child. Methods:Thirty-three transgenic mice replicating high levels of HBV were randomly allocated into 3 groups,each group of eleven mice. Pregnant HBV transgenic mice in experimental groups,Group A were given normal saline and Group B were given orally telbivudine (600mg/kg/d) from mating to delivery,Group C were given orally telbivudine (1200mg/ kg/d).The changes of serum HBsAg,HBV DNA before and after the treatment were detected. At the same time,eleven C57BL /6J female mice (D) were given telbivudine (600mg/kg/d).The safety indexes of pregnant mice,fetus and newborns in experimental groups and control groups were observed. Newborns were detected about the changes of serum HBsAg and HBV DNA. Liver tissue was examined by immunohistochemical method. Results:The average serum HBsAg titers from mice in experimental Group A was no significant difference between before and after the treatment (P>0.05),while Group B and Group C were lowered after drug treatment (P<0.05). The serum HBV DNA titers from mice in each experimental groups was no significant difference between before and after the treatment (P> 0.05). No significant abnormalities of live fetus was observed. The postnatal survival and weight of live pups were not different between the groups. The liver tissue of newborn was collected to detect negative HBsAg in the cells by immunohistochemical method.Conclusions:Effective telbivudine treatment during gestation can prevent HBV mother-to-child. It has no significant adverse effect on safety of pregnant mice and their offspring.